EVALUATION OF THE HIGH-SENSITIVITY C-REACTIVE PROTEIN IN YOUNG OBESE WOMEN WITH PCOS
| Autor: | Indira Palo, Sura Kishore Mishra |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
endocrine system diseases biology lcsh:R5-130.5 business.industry C-reactive protein nutritional and metabolic diseases female genital diseases and pregnancy complications Endocrinology Internal medicine Hs-CRP PCOS CVD biology.protein Medicine Obesity Sensitivity (control systems) business lcsh:General works |
| Zdroj: | Journal of Evidence Based Medicine and Healthcare, Vol 5, Iss 1, Pp 80-84 (2018) |
| ISSN: | 2349-2570 2349-2562 |
| DOI: | 10.18410/jebmh/2018/18 |
| Popis: | BACKGROUND The Polycystic Ovarian Syndrome (PCOS) is one of the most common reproductive disorder in young women affecting 5-10% of population. PCOS women are at increased risk of developing metabolic syndrome, type 2 diabetes mellitus and cardiovascular diseases. PCOS is now recognised as not only a reproductive disorder, but also a metabolic one with long-term effects on women’s health. With this background, the present study was undertaken to assess the levels of High-Sensitivity C-Reactive Protein (hs-CRP) in young obese women with PCOS as compared with healthy obese women without PCOS. MATERIALS AND METHODS This cross-sectional observational study was carried out in MKCG Medical College, Berhampur, in the Department of Cardiology and Gynaecology between January 2016 to December 2016. A total of 56 young obese PCOS patients aged less than 30 years and 25 healthy patients matched for age and BMI were studied. RESULTS Baseline cardiovascular risk factors, hormone variables and lipid profiles and hs-CRP levels are measured in both PCOS patients and control subjects. It has been observed that the median hs-CRP levels are significantly higher in young obese PCOS patients than the control subjects. Obese patients with PCOS had higher levels of hs-CRP compared to healthy obese controls. The mean values of hs-CRP was 5.46 mg/L in PCOS group and 2.8 mg/L in the control group, which is statistically significant. CONCLUSION PCOS patients clearly present a higher risk of CVD due to its peculiar hormonal pattern characterised by insulin resistance, dyslipidaemia and inflammatory state. The metabolic disorders in PCOS could possibly be improved by diet and drugs in early periods of their life, so as to decrease the risk of CVD in future. Estimation hs-CRP maybe considered as a reliable predictive marker for future Cardiovascular Disease (CVD) in PCOS patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|